ID   BLIN-1
AC   CVCL_8173
SY   Blin-1; Blin1; B-lineage 1
DR   BioSample; SAMN03151850
DR   cancercelllines; CVCL_8173
DR   Cosmic; 1070705
DR   GEO; GSM3145692
DR   Wikidata; Q54797358
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2642502;
RX   PubMed=7919343;
RX   PubMed=12592342;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a NALM-6 derivative (PubMed=12592342; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00170.
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 50800; DUX4 + HGNC; 5477; IGH; Name(s)=IGH-DUX4; Note=The translocation occurs in the silenced IGH allele (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0092 ! NALM-6
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 29
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2642502; DOI=10.4049/jimmunol.142.1.110;
RA   Wormann B., Anderson J.M., Liberty J.A., Gajl-Peczalska K.,
RA   Brunning R.D., Silberman T.L., Arthur D.C., LeBien T.W.;
RT   "Establishment of a leukemic cell model for studying human pre-B to B
RT   cell differentiation.";
RL   J. Immunol. 142:110-117(1989).
//
RX   PubMed=7919343; DOI=10.1182/blood.V84.7.2253.2253;
RA   Renard N., Duvert V., Banchereau J., Saeland S.;
RT   "Interleukin-13 inhibits the proliferation of normal and leukemic
RT   human B-cell precursors.";
RL   Blood 84:2253-2260(1994).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//